Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have been given an average recommendation of “Buy” by the eight brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $37.40.

A number of research analysts recently weighed in on the company. Chardan Capital upgraded Seres Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $27.50 to $30.00 in a report on Thursday, March 11th. Oppenheimer reiterated a “buy” rating and issued a $38.00 target price on shares of Seres Therapeutics in a report on Tuesday, March 2nd. Finally, Zacks Investment Research cut Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 25th.

Shares of NASDAQ:MCRB traded up $1.17 during midday trading on Tuesday, reaching $21.52. The company’s stock had a trading volume of 108,850 shares, compared to its average volume of 973,772. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of -18.39 and a beta of 4.07. The company has a quick ratio of 6.73, a current ratio of 6.73 and a debt-to-equity ratio of 0.13. Seres Therapeutics has a 1 year low of $3.41 and a 1 year high of $38.50. The business has a 50 day moving average price of $20.53 and a 200 day moving average price of $25.02.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Monday, March 1st. The biotechnology company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.05. The business had revenue of $17.56 million during the quarter, compared to the consensus estimate of $8.78 million. Seres Therapeutics had a negative return on equity of 2,867.98% and a negative net margin of 385.22%. Sell-side analysts anticipate that Seres Therapeutics will post -1.14 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC bought a new position in shares of Seres Therapeutics during the third quarter valued at approximately $339,000. Sei Investments Co. acquired a new position in shares of Seres Therapeutics during the third quarter worth approximately $611,000. HM Payson & Co. acquired a new position in shares of Seres Therapeutics during the third quarter worth approximately $28,000. Columbus Circle Investors acquired a new position in shares of Seres Therapeutics during the fourth quarter worth approximately $3,797,000. Finally, Pacer Advisors Inc. acquired a new position in shares of Seres Therapeutics during the fourth quarter worth approximately $133,000. 94.32% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

Further Reading: Dividend Reinvestment Plan (DRIP)

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.